Eli Lilly’s Tirzepatide Receives NICE Recommendation for the Treatment of Type 2 Diabetes
Shots:
- The NICE has issued the final draft guidance recommending Eli Lilly’s Tirzepatide, also known as Mounjaro for the treatment of inadequately controlled type 2 diabetes in adults alongside diet and exercise
- The clinical trial results showed that the patients treated with Tirzepatide substantially declined blood sugar levels & body weight over insulin therapy, semaglutide, or a PBO. Tirzepatide demonstrated that 81%-97% of patients achieved better glucose control, 54%-88% reached a ≥5% reduction in body weight
- Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist was approved in the US in May 2022 for T2D & also approved in the EU in Sept 2022
Ref: Nice | Image: Eli Lilly
Related News:- Eli Lilly Reports P-III (SURMOUNT-3 & 4) Studies Results of Tirzepatide for the Treatment of Obesity and Overweight
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
